phosphatidylinositol transfer protein cytoplasmic 1Genealiases: M-RDGB-beta · MRDGBbeta · RDGB-BETA · RDGBB · RDGBB1
Q-omics provides the consensus-scored PITPNC1 profile across patient tissues and cancer cell-line models. PITPNC1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PITPNC1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, PITPNC1 RNA expression shows 18,794 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where PITPNC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PITPNC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PITPNC1 survival associations across molecular data types. PITPNC1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PITPNC1 RNA expression–survival associations across cancer types. High PITPNC1 expression shows unfavorable associations in UVM, ACC, LUAD and THCA, but favorable associations in KIRC and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PITPNC1 RNA expression.
This table summarizes PITPNC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PITPNC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PITPNC1 shows lower tumor expression in KICH and higher tumor expression in KIRC, COAD, LIHC, STAD and LUAD. The KIRC box plot shows higher PITPNC1 RNA expression in tumor versus normal tissue (log2 FC = +1.285, t-test p < 0.001).
This table shows molecular features associated with PITPNC1 in patient tissues and cancer cell lines. In patient samples, PITPNC1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PITPNC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
